TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer’s disease
The recent Phase Ib/IIa interim results suggest that rapid and robust amyloid plaque clearance and fluid biomarker changes may be achieved with low ARIA incidence. The overall favorable safety and interim biomarker results to date support the rationale for moving into the pivotal Phase III studies TRONTIER 1 and TRONTIER 2. These studies will provide the opportunity to assess whether treatment with trontinemab slows disease progression in people living with early symptomatic AD.
Authors
- Ruth Croney (ORCID: https://orcid.org/0009-0004-8176-3073)
- Luka Kulic (ORCID: https://orcid.org/0000-0003-3427-9436)
- Hideki Garren
- Chris Lane (ORCID: https://orcid.org/0000-0002-1956-8064)
- Angeliki Thanasopoulou
- Paul Delmar (ORCID: https://orcid.org/0000-0002-2095-6283)
- Janice Smith (ORCID: https://orcid.org/0000-0002-7267-5774)
- Carsten Hofmann
- Jakub Wojtowicz (ORCID: https://orcid.org/0009-0007-6659-8008)
- Gregory Klein
- Henrik Zetterberg
- Jeffrey L. Cummings
- Gil D. Rabinovici
- Reisa A. Sperling
- Stephen Salloway
- Catherine J. Mummery
Institutions
- Roche (Switzerland) (CH)
- University of Nevada, Las Vegas (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Butler Hospital (US)
- Massachusetts General Hospital (US)
- Roche (United Kingdom) (GB)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104294
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00